Graphene oxide reinforced SrHAP composite as a drug carrier in bone regeneration.

Autor: Murugan E; Department of Physical Chemistry, School of Chemical Sciences, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India. Electronic address: dr.e.murugan@gmail.com., Akshata CR; Department of Physical Chemistry, School of Chemical Sciences, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India. Electronic address: akshata.bang@gmail.com.
Jazyk: angličtina
Zdroj: Colloids and surfaces. B, Biointerfaces [Colloids Surf B Biointerfaces] 2022 Nov; Vol. 219, pp. 112822. Date of Electronic Publication: 2022 Sep 05.
DOI: 10.1016/j.colsurfb.2022.112822
Abstrakt: Strontium substituted HAP (SrHAP), with a 10 mol% substitution, was mineralized on increasing weight percentages of graphene oxide (2, 4 and 6). The GS composites were comprehensively characterized for drug delivery in bone reconstruction. The formation of SrHAP was verified by XRD and FT-IR results. The apatite crystallization was influenced by graphene oxide content and strontium. The EDS results confirmed the presence of strontium and HR-SEM depicted rod shape apatite, of length between 58 and 135 nm, uniformly embedded on graphene oxide. The reinforcement of graphene oxide increased the surface area, porosity, microhardness (upto 0.59 GPa), protein adsorption (upto 18.16 μg/mg), water uptake and degradation properties. Also, the increase in graphene oxide fraction significantly enhanced the curcumin encapsulation efficiency (upto 80.16%) and the drug release was considerably retarded over SrHAP. The in vitro studies using human osteoblast-like MG-63 cells demonstrated that curcumin-loaded composite was biocompatible and promoted proliferation, differentiation and matrix mineralization. The results highlight the combinational therapy of osteogenic ion (strontium) and osteogenic drug (curcumin) as a promising platform in bone tissue engineering.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: